Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes

Pharming Group's core RUCONEST franchise has shown a sequential sales rebound, supporting a cautiously more optimistic outlook. Oral competitive therapies remain a material risk to stabilizing RUCONEST revenue, but a manageable erosion scenario could provide time for Joenja to grow and improve the company's revenue mix.

Analysis

PHAR remains a concentrated-asset equity, so the relevant question is not whether near-term sales stabilize but whether management can preserve enough cash generation to fund Joenja commercialization without dilution. Oral hereditary-angioedema therapies raise the switching risk for acute-treatment patients, making the revenue base more vulnerable to gradual share loss than a single-quarter rebound implies. The key second-order issue is payer behavior: formulary preference for convenient oral agents could compress PHAR's net pricing before it is visible in reported prescription volume.

Over the next 1-3 months, PHAR can outperform if quarterly RUCONEST revenue and full-year guidance demonstrate that competitive leakage has plateaued. Over 6-18 months, valuation depends on Joenja patient identification, diagnosis conversion, and persistence; the addressable population is small enough that execution misses can materially alter the growth narrative. A sustainable mix shift toward Joenja would merit a higher multiple, while renewed dependence on RUCONEST would leave PHAR valued as an ex-growth, single-product rare-disease company.

The contrarian case is that the market may be underestimating the scarcity value of an approved treatment in APDS if diagnosis rates improve through physician education and genetic testing. Conversely, the bull case is falsified if RUCONEST revenue declines reaccelerate for two consecutive quarters, Joenja adds fail to offset the lost gross profit, or cash runway assumptions require an equity raise. Competitive read-through should come from BCRX prescription trends and any payer-access changes around oral HAE alternatives.

Key Decisions for Investors

• Maintain PHAR on a watchlist rather than initiating before the next earnings release; require sequential RUCONEST stability and reaffirmed guidance as confirmation. A guidance cut or a renewed double-digit year-on-year decline in the legacy franchise is a no-go signal.
• For a small tactical long, enter PHAR only after earnings confirmation and size it as a high-volatility biotech position; target a 15-25% upside rerating from evidence of Joenja growth plus stable cash burn, with a hard exit on a revenue-guide reduction or financing announcement.
• Use BCRX as the competitive monitoring proxy: accelerating ORLADEYO demand or improved payer access would increase the probability of PHAR multiple compression over the following 1-2 quarters, arguing against owning PHAR through that inflection.
• Do not express the thesis with options until implied volatility, liquidity, and available expiries are reviewed; the missing inputs are option spreads and the market-implied post-earnings move.